{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T10:44:18Z","timestamp":1760784258865},"reference-count":10,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1097\/mnm.0000000000000665","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T18:36:22Z","timestamp":1491417382000},"page":"407-414","source":"Crossref","is-referenced-by-count":2,"title":["Spectrum of metastatic and nonmetastatic skeletal findings with dual-phase 18F-FECH PET\/CT in patients with biochemical relapse of prostate cancer"],"prefix":"10.1097","volume":"38","author":[{"given":"Athar","family":"Haroon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rizwan","family":"Syed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raymond","family":"Endozo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rayjanah","family":"Allie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alex","family":"Freeman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark","family":"Emberton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jamshed","family":"Bomanji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-8-20210212","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich","year":"2014","journal-title":"Eur Urol"},{"key":"R2-8-20210212","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/08998280.2005.11928089","article-title":"Use of PET\/CT scanning in cancer patients: technical and practical considerations","volume":"18","author":"Griffeth","year":"2005","journal-title":"Proc (Bayl Univ Med Cent"},{"key":"R3-8-20210212","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2967\/jnumed.110.077941","article-title":"Prostate cancer: PET with 18F-FDG, 18F- or 11C-acetate, and 18F- or 11C-choline","volume":"52","author":"Jadvar","year":"2011","journal-title":"J Nucl Med"},{"key":"R4-8-20210212","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/s00259-015-3202-7","article-title":"PET\/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data","volume":"43","author":"Fanti","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R5-8-20210212","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1007\/s00256-014-1903-9","article-title":"Comparison of choline-PET\/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis","volume":"43","author":"Shen","year":"2014","journal-title":"Skeletal Radiol"},{"key":"R6-8-20210212","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S0022-5347(05)64906-3","article-title":"Comparison of [18F]fluorocholine and [18F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer","volume":"168","author":"Price","year":"2002","journal-title":"J Urol"},{"key":"R7-8-20210212","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1097\/MNM.0000000000000372","article-title":"Multicenter study evaluating extraprostatic uptake of 11C-choline, 18F-methylcholine, and 18F-ethylcholine in male patients: physiological distribution, statistical differences, imaging pearls, and normal variants","volume":"36","author":"Haroon","year":"2015","journal-title":"Nucl Med Commun"},{"key":"R8-8-20210212","first-page":"187","article-title":"Development of (18)F-fluoroethylcholine for cancer imaging with PET: synthesis, biochemistry, and prostate cancer imaging","volume":"43","author":"Hara","year":"2002","journal-title":"J Nucl Med"},{"key":"R9-8-20210212","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1200\/JCO.2015.65.7270","article-title":"Meta-analysis evaluating the impact of site of metastasis on overall survival in men with castration-resistant prostate cancer","volume":"34","author":"Halabi","year":"2016","journal-title":"J Clin Oncol"},{"key":"R10-8-20210212","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1007\/s11307-009-0217-0","article-title":"The use of F-18 choline PET in the assessment of bone metastases in prostate cancer: correlation with morphological changes on CT","volume":"11","author":"Beheshti","year":"2009","journal-title":"Mol Imaging Biol"}],"container-title":["Nuclear Medicine Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MNM.0000000000000665","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T03:35:31Z","timestamp":1620963331000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006231-201705000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":10,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/mnm.0000000000000665","relation":{},"ISSN":["0143-3636"],"issn-type":[{"value":"0143-3636","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]}}}